Sanofi India announced its financial results for the quarter and half-year ended June 30, 2026. The company reported a significant 19% increase in profit before tax to INR 112 crore for the quarter, compared to INR 94 crore in the previous year. This growth was driven by a robust performance in its diabetes portfolio, which saw double-digit growth.
Sanofi India Reports Strong Q2 2026 Financial Performance
Sanofi India Limited has announced its financial results for the quarter and half-year ended June 30, 2026. The company demonstrated strong performance, with profit before tax (PBT) increasing by 19% to INR 112 crore for the second quarter of 2026, up from INR 94 crore in the corresponding period of 2025. This marks a continued profit momentum for the company.
Diabetes Portfolio Drives Growth
The company’s impressive results were significantly influenced by the robust performance of its diabetes portfolio. The insulin segment continued its strong trajectory, achieving double-digit growth of 14% for the second consecutive quarter. This reinforces Sanofi’s leadership in the basal analog market, holding a substantial 58% value market share and 61% volume market share. Growth in this segment was powered by key products such as Lantus®, Toujeo®, Apidra®, and Soliqua®.
Public Sector Business Accelerates
Sanofi India’s public sector business also saw significant acceleration, growing by 70%. This growth was attributed to the acquisition of new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, further solidifying Sanofi’s presence in the diabetes injectable space.
Strategic Partnerships and Export Stability
Strategic partnerships in the Cardiovascular, Oral anti-Diabetes, and Central Nervous System segments have established a strong foundation for market reach expansion, with partnership revenues growing 2% in Q2 2026. Export sales remained stable, highlighting the resilience of Sanofi India’s international operations amidst global economic headwinds.
Improved Profitability and Cost Management
The profit before tax as a percentage of net sales improved to 27% in Q2 2026, an increase from 24% in Q2 2025. This improvement is a result of a favorable product mix and disciplined cost management, with operating expenses declining by 5% compared to the second quarter of 2025. The company also reported its unaudited financial results for the half-year ended June 30, 2026, along with a review report from its statutory auditors.
Committee Re-constitution
The Board of Directors also approved the re-constitution of the Stakeholders Relationship Committee and the Risk Management Committee, effective from October 1, 2026. Details of the members and their positions within these committees were also disclosed.
Source: BSE
